Status:
COMPLETED
Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
Lead Sponsor:
Toronto Rehabilitation Institute
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Fatigue, reduced quality of life and declines in physical function are common in patients undergoing chemotherapy for acute myeloid leukaemia (AML). Studies in other cancer patients undergoing treatme...
Detailed Description
Background: Acute myeloid leukaemia (AML) is a life-threatening haematological malignancy. Initial treatment with induction chemotherapy requires 4-5 weeks of hospitalization, with a risk of physical ...
Eligibility Criteria
Inclusion
- at least 18 years old
- newly diagnosed AML, or relapsed AML after having been in complete remission for at least 6 months
- initiating induction chemotherapy
- ambulatory without need for human assistance
- has consented to study
- is medically cleared for participation by attending physician
Exclusion
- has another active malignancy
- has life expectancy \< 1 month, physician determined
- has significant comorbidity
- has uncontrolled pain
- has haemodynamic instability
- lacks fluency in reading and writing English and there is no translator available for each visit
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01170598
Start Date
June 1 2010
End Date
March 1 2011
Last Update
April 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9